As of 2025-09-17, the Relative Valuation of Summit Therapeutics Inc (SMMT) is (1.64) USD. This relative valuation is based on P/E multiples. With the latest stock price at 18.12 USD, the upside of Summit Therapeutics Inc based on Relative Valuation is -109.1%.
The range of the Relative Valuation is (1.30) - (2.17) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 4.4x - 11.4x | 7.9x |
| Forward P/E multiples | 6.8x - 11.9x | 9.4x |
| Fair Price | (1.30) - (2.17) | (1.64) |
| Upside | -107.1% - -112.0% | -109.1% |
| Date | P/E |
| 2025-09-16 | -95.11 |
| 2025-09-15 | -99.41 |
| 2025-09-12 | -99.41 |
| 2025-09-11 | -97.63 |
| 2025-09-10 | -92.41 |
| 2025-09-09 | -98.81 |
| 2025-09-08 | -102.06 |
| 2025-09-05 | -136.36 |
| 2025-09-04 | -124.92 |
| 2025-09-03 | -123.45 |
| 2025-09-02 | -125.13 |
| 2025-08-29 | -124.40 |
| 2025-08-28 | -128.18 |
| 2025-08-27 | -130.20 |
| 2025-08-26 | -141.61 |
| 2025-08-25 | -137.89 |
| 2025-08-22 | -137.52 |
| 2025-08-21 | -136.52 |
| 2025-08-20 | -135.79 |
| 2025-08-19 | -133.06 |
| 2025-08-18 | -137.99 |
| 2025-08-15 | -140.09 |
| 2025-08-14 | -138.83 |
| 2025-08-13 | -141.04 |
| 2025-08-12 | -134.82 |
| 2025-08-11 | -148.28 |
| 2025-08-08 | -150.43 |
| 2025-08-07 | -147.33 |
| 2025-08-06 | -149.70 |
| 2025-08-05 | -152.90 |
| 2025-08-04 | -153.90 |
| 2025-08-01 | -142.09 |
| 2025-07-31 | -138.41 |
| 2025-07-30 | -139.93 |
| 2025-07-29 | -140.35 |
| 2025-07-28 | -144.08 |
| 2025-07-25 | -150.48 |
| 2025-07-24 | -144.71 |
| 2025-07-23 | -147.02 |
| 2025-07-22 | -139.30 |
| 2025-07-21 | -138.25 |
| 2025-07-18 | -137.52 |
| 2025-07-17 | -145.03 |
| 2025-07-16 | -148.38 |
| 2025-07-15 | -127.86 |
| 2025-07-14 | -133.32 |
| 2025-07-11 | -131.22 |
| 2025-07-10 | -135.84 |
| 2025-07-09 | -129.86 |
| 2025-07-08 | -120.67 |